Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 12:15:396.
doi: 10.1186/s12885-015-1260-7.

Preoperative serum CA125: a useful marker for surgical management of endometrial cancer

Tao Jiang  1 , Ling Huang  2 , Shulan Zhang  3
Affiliations

Preoperative serum CA125: a useful marker for surgical management of endometrial cancer

Tao Jiang et al. BMC Cancer. .

Abstract

Background: Surgery plays an important role in the management of endometrial cancer at all stages, particularly early clinical stage. There are still many unanswered questions regarding optimal surgical management of endometrial cancer, particularly regarding which patients should undergo lymphadenectomy. The aim of this study was to evaluate the role of preoperative cancer antigen 125 (CA125) serum levels for surgical management in endometrial cancer patients.

Methods: A total of 995 patients with endometrial cancer, according to inclusion criteria of a preoperative serum level of CA125, were selected. The association between clinicopathological factors and CA125 were analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the role of preoperative serum CA125 in predicting lymph node metastasis, adnexal involement, cervical stromal invasion in all patients, especially patients with clinical stage I. Survival analyses were also performed according to the four groups of preoperative CA125 serum levels.

Results: Elevated CA125 level was significantly associated with all clinicopathological parameters, including age and menopause, but not histology type. ROC curve analysis results showed the CA125 serum level of 25 U/mL was the best cutoff to predict the lymph node metastasis. It was with 78% of sensitivity, 78% of specificity, 77.6% of false positive rate, 2.3% of false negative rate in all patients. In patients with clinical stage I, it was with 71.7% of sensitivity, 77.6% of specificity, 83.3% of false positive rate, 2.2% of false negative rate. The best cutoff to evaluate adnexal involement in patients with clinical stage I was 30U/ml, with 81% sensitivity, and 78.4% specificity. Survival analysis revealed CA125, FIGO stage, histology grade, and positive peritoneal cytology as independent prognostic factors of endometrial cancer.

Conclusion: Preoperative serum CA125 is an important predictor for patients with endometrial cancer and it should be taken into consideration when surgical management is determined, especially if a lymphadenectomy should be undertaken in patients with clinical stage I.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The receiver operating characteristic (ROC) curve of preoperative serum CA125 for predicting lymph node metastasis. (A) All patients with lymph node metastasis. (B) Patients with only lymph node metastasis without adnexal involvement, distant metastasis and positive peritoneal cytology.
Figure 2
Figure 2
The receiver operating characteristic (ROC) curve of preoperative serum CA125 for predicting lymph node metastasis in patients with clinical stage I. (A) All patients with lymph node metastasis. (B) Patients with only lymph node metastasis without adnexal involvement, distant metastasis and positive peritoneal cytology.
Figure 3
Figure 3
The receiver operating characteristic (ROC) curve of preoperative serum CA125 for predicting adnexal involvement in patients with clinical stage I. (A) All patients with adnexal involement. (B) Premenopausal patients with adnexal involement.
Figure 4
Figure 4
Survival curves in relation to different preoperative serum CA125 group. Prognosis worsened with increasing level of CA125 (χ2 = 186.60, P < 0.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505. doi: 10.1016/S0140-6736(05)67063-8. - DOI - PubMed
    1. Beesley VL, Rowlands IJ, Hayes SC, Janda M, O’Rourke P, Marquart L, et al. Incidence, risk factors and estimates of a woman’s risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncol. 2015;136:87–93. doi: 10.1016/j.ygyno.2014.11.006. - DOI - PubMed
    1. Salani R, Preston MM, Hade EM, Johns J, Fowler JM, Paskett EP, et al. Swelling among women who need education about leg lymphedema: a descriptive study of lymphedema in women undergoing surgery for endometrial cancer. Int J Gynecol Cancer. 2014;24:1507–12. doi: 10.1097/IGC.0000000000000226. - DOI - PMC - PubMed
    1. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27:5331–6. doi: 10.1200/JCO.2009.22.3248. - DOI - PMC - PubMed
    1. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr, Knapp RC, Bast RC., Jr Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984;148:1057–8. doi: 10.1016/S0002-9378(84)90444-7. - DOI - PubMed

MeSH terms